Jordi Visser

getting the Nobel Prize.

And he said in January of this year, and he said it on a 60 Minutes, which everyone should go watch, by the end of this year, we will have AI

drugs going into clinical trials.

Now, what this will do is people will start to realize how much is spent on R&D.

Both time and massive amounts of money where 90% of every drug never even make it to trial.

So the failure rate is very high.

So the amount of money wasted on things, what they're doing is saying, no, this is the blueprint like Moderna that's gonna get you this.

What Insilico does is they're the engineer that goes through and starts creating what would actually work.

And then Eli Lilly is the manufacturer.

So this is kind of like this process of going from idea to solve a problem.

Oh, okay, let's test it out and see if it gets, get it to clinical trial.

So I don't want to make this too long, but this is part of the story.

Google DeepMind hired a chief medical officer who's an expert in getting things through clinical trials back in June, Ben Wolfe.

They have talked openly about being close.

And there's a bunch of interviews that people at Isomorphic have talked about.

Now they can't say exactly what's going on, but this is related to cancer.

That's where their focus has been.

Their focus has been on cancer.

Eli Lilly announced an upgrade in silico relationship this week.

All of this stuff has happened in the last three weeks.